Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience - A Multicenter Retrospective Study.

Abstract

INTRODUCTION:

This study examined real-world data from patients who received eribulin for metastatic breast cancer (MBC) collected from 14 hospitals across the UK.

METHODS:

Anonymized data were collected retrospectively from patients with MBC who had received eribulin. The data included the hormone-receptor status, histological diagnosis, age, prior chemotherapy, response to eribulin, progression-free survival (PFS), and overall survival (OS).

RESULTS:

Among 577 patients analyzed, the median age was 56 years, and most patients (73%) were estrogen-receptor positive. The median OS was 288 days (95% confidence interval [CI]: 261-315), and the PFS was 117 days (95% CI: 105-129). The median OS was higher among older patients (≥65 vs. <65 years: 325 days [95% CI: 264-385] vs. 285 days [95% CI: 252-317]; p = 0.028). The median OS was also higher in patients who received eribulin after fewer prior lines of chemotherapy (≤2 vs. >2 prior: 328 days [95% CI: 264-385] vs. 264 days [95% CI: 229-298]; p = 0.042).

DISCUSSION/CONCLUSION:

These retrospective data suggest that eribulin can be successfully used in older patients with MBC. Eribulin treatment was more effective in earlier-line settings, which, while predictable, supports consideration of eribulin as a second-line treatment option.

• Authors: Mariam Jafri, Hartmut Kristeleit, Vivek Misra, Mark Baxter, Samreen Ahmed, Apurna Jegannathen, Ankit Jain, David Maskell, Urmila Barthakur, Gwenllian Edwards, Harriet S Walter, Richard Walshaw, Madeha Khan, Annabel Borley, Daniel Rea
• Journal: Oncology (Oncology) Vol. 100 Issue 12 Pg. 666-673 ( 2022) ISSN: 1423-0232 [Electronic] Switzerland
• PMID: 36044833 (Publication Type: Multicenter Study, Journal Article)
• Copyright: © 2022 The Author(s). Published by S. Karger AG, Basel.

Chemical References

• eribulin
• Furans
• Ketones

Topics

• Humans
• Aged
• Middle Aged
• Female
• Breast Neoplasms (pathology)
• Retrospective Studies
• Furans (therapeutic use)
• Ketones (therapeutic use)
• United Kingdom
• Treatment Outcome